Transcelerate teams to take on investigator selection bias
Transcelerate announced it had partnered to develop Investigator Registry (IR) this week, explaining that member companies will pool data on the staff that run trials which will be stored in a database hosted by DrugDev.
The idea is to allow Transcelerate's member companies to select clinical trial investigators based on their past performance and expertise according to a spokeswoman for the industry group.
She told Outsourcing-pharma.com that: “Today, investigator selection is largely based on previous study experience and local site relationships.
“The IR attempts to broaden the process by providing clinical operations professionals with the integrated data they need to make smart site selection decisions, and by ensuring that sites have direct access to appropriate trial opportunities."
She added that: “As the IR is adopted by more and more participating TransCelerate member companies, our vision is that the investigator selection bias that exists today will eventually be replaced by a more evidence-driven process.”
Each investigator stored in the database will be assigned a “golden number” that links details of that person’s experience to data stored in Transcelerate’s existing Shared Investigator Platform (SIP).
The spokeswoman said: “Examples of data fields to be included in the registry: person contact information, TransCelerate CV, facility contact information, TransCelerate site profile form, protocol information, and historical study metrics.”
She added that: “For pharmaceutical companies, the ability to expeditiously find investigator matches for their trials will drive improved performance – including faster study start-up, faster patient recruitment, increased patient retention, enhanced operational efficiencies, and fewer non-performing or under-performing sites.
